DaVita (DVA) stock
Health Care · Health Care Services
DaVita (DVA) is a Health Care Services company in the Health Care sector, headquartered in Denver, Colorado. As of October 23, 2026, DVA closed at $183.64, a market capitalization of $11.72 billion, the 477th largest company in the S&P 500. Over the last twelve months it generated $14.01 billion in revenue (+5% year over year) and $1.61 billion in free cash flow. The stock trades at 15.5x trailing earnings and 10.7x forward earnings.
- 1-year total return: +43.4% (dividends reinvested)
- 5-year return: +9.7% a year
- 52-week range: $101.00 – $247.49
- Gross margin 32.4%, operating margin 16.1%
- FI Handbook report card: B- across 10 metrics
- 54th largest of 60 Health Care stocks in the S&P 500
DVA price chart
1Y price change: +43.4% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| DVA | +0.3% | +61.6% | +43.4% | +32.5% | +9.7% | +11.7% | +13.1% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1995.
DVA key statistics
- Market cap
- $11.7B
- #477 in S&P 500
- P/E (TTM)
- 15.5x
- Forward P/E
- 10.7x
- EPS (TTM)
- $11.84
- Revenue (TTM)
- $14.0B
- +5%
- Free cash flow
- $1.6B
- Gross margin
- 32.4%
- Operating margin
- 16.1%
- Return on equity
- 88.5%
- Dividend yield
- None
- 52-week range
- $101.00 – $247.49
- Beta
- 0.80
- Price / sales
- 0.8x
- EV / EBITDA
- 9.3x
- Debt / equity
- 12.42x
- Employees
- 78,000
DVA report card
B-Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth5.2%C
- Gross margin32.4%C
- Operating margin16.1%C
- FCF margin11.5%C
- Return on equity88.5%A
- Net debt / EBITDA4.5xF
- Forward P/E10.7xA
- PEG ratio0.4xA
- Shareholder yield11.2%A
- Share count change / yr-9.2%A
DaVita financials
Revenue went from $10.7B in fiscal 2016 to $13.6B in fiscal 2025, growing 2.7% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.7B | $10.9B | $11.4B | $11.4B | $11.6B | $11.6B | $11.6B | $12.1B | $12.8B | $13.6B |
| Operating income | $2.0B | $1.8B | $1.5B | $1.6B | $1.7B | $1.8B | $1.3B | $1.6B | $2.1B | $2.0B |
| Net income | $879.9M | $663.6M | $159.4M | $811.0M | $773.6M | $978.5M | $560.4M | $691.5M | $936.3M | $746.8M |
| EPS (diluted) | $4.29 | $3.47 | $0.92 | $5.27 | $6.31 | $8.90 | $5.85 | $7.42 | $10.73 | $9.84 |
| Free cash flow | $1.1B | $1.0B | $784.5M | $1.3B | $1.3B | $1.3B | $961.1M | $1.5B | $1.5B | $1.3B |
| Buybacks | $1.1B | $802.9M | $1.2B | $2.4B | $1.5B | $1.5B | $802.2M | $272.2M | $1.4B | $1.3B |
| Dividends paid | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Diluted shares | 204.9M | 191.3M | 172.4M | 153.8M | 122.6M | 109.9M | 95.8M | 93.2M | 87.3M | 75.9M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into DVA?
A reverse DCF asks what growth the current price requires. With an enterprise value of $24.4B and $1.6B of trailing free cash flow, DaVita needs to grow free cash flow about 3.8% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 0.1% a year over the last five years.
P/E ratio history
Current 18.7x vs. median 17.2x (10th–90th percentile 11.0x–35.8x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
DVA analyst price targets
7 analysts' average 12-month target is $219.86 (+20% vs. $183.64). Targets range from $165.00 to $270.00. 38% rate it a buy.
DVA earnings
Next report: October 29, 2026. DaVita has beaten EPS estimates 3 quarters in a row. Last quarter's revenue was $3.6B (+5% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 4, 2026 | $3.88 | $4.02 | +3.5% |
| May 5, 2026 | $2.33 | $2.87 | +23.2% |
| Feb 2, 2026 | $3.19 | $3.40 | +6.5% |
| Oct 29, 2025 | $3.17 | $2.51 | -20.9% |
| Aug 5, 2025 | $2.75 | $2.95 | +7.3% |
| May 12, 2025 | $2.02 | $2.00 | -0.9% |
| Feb 13, 2025 | $2.13 | $2.24 | +5.4% |
| Oct 29, 2024 | $2.72 | $2.59 | -4.9% |
Stocks like DVA
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 CVS CVS Health | -1.07% | +19% | $119.5B | 24.6x | Compare |
 CI Cigna | -2.83% | +3% | $81.1B | 12.7x | Compare |
 DGX Quest Diagnostics | -0.57% | +34% | $26.7B | 24.1x | Compare |
 LH Labcorp | -0.30% | +17% | $26.7B | 27.2x | Compare |
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
 JNJ Johnson & Johnson | -1.42% | +40% | $635.1B | 40.0x | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
DVA news
- How Investors Are Reacting To DaVita (DVA) Kidney Week Research Push · Oct 25, 2026
- Is DaVita (DVA) Still Reasonable After Its 139% Three Year Run? · Oct 25, 2026
- DaVita (DVA) Settles Ransomware Case As Kidney Week Research Takes Center Stage · Oct 24, 2026
- DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? · Oct 22, 2026
- Outpatient & specialty care stocks Q2 teardown: DaVita (NYSE:DVA) vs the rest · Oct 22, 2026
DVA stock FAQ
What is DVA's market cap?
DaVita's market capitalization is $11.72 billion as of October 23, 2026, ranking 477th in the S&P 500.
What is DVA's P/E ratio?
DVA trades at a trailing price-to-earnings ratio of 15.5x and a forward P/E of 10.7x. Its median P/E over the period we track is 17.2x.
Does DVA pay a dividend?
No. DaVita does not currently pay a regular cash dividend.
How much has DVA stock returned?
Including reinvested dividends, DVA returned +43.4% over one year, +9.7% a year over five years, +11.7% a year over ten years through October 23, 2026.
Is DVA stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies DaVita must grow free cash flow about 4% a year for the next decade. Its free cash flow grew 0% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the DVA price target?
7 analysts cover DVA with an average 12-month price target of $219.86, +20% from the current price. 38% of them rate it a buy.
When does DVA report earnings?
DaVita is expected to report earnings on October 29, 2026. It has beaten EPS estimates 3 quarters in a row.
How many employees does DaVita have?
DaVita has about 78,000 full-time employees, or $179,611 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology